LetsAnalyzeandTalk

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter Link in the comments #Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter Link in the comments #Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter Link in the comments #Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter Link in the comments #Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter Link in the comments #Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter Link in the comments #Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

#ASCO26 - #ASCO26 is starting soon, and we’ll be tracking the data, practice‑changing trials and real‑time highlights – follow all the latest #ASCO2026 updates in one place at @ipharmacenter Link in the comments #Cancer #OncoAlert #ASCO26 #ASCO2026 #innovation #oncology

#Bimzelx supera #Skyrizi nello studio testa-a-testa sull’artrite psoriasica presentato a #EULAR2026. Alla settimana 16, ACR50: 49,1% vs 38,4%, con insorgenza più rapida e ottimi risultati cutanei e articolari nello studio BE BOLD ipharmacenter.com/post/eular-ann… #EULAR26 #Sanità #Psoriasi

Johnson and Johnson made $94.2B in 2025. #EliLilly grew 45% to $65.2B. #NovoNordisk hit $49B on Ozempic and Wegovy alone. Full top 10 breakdown ipharmacenter.com/post/top-10-ph… #Pharma #BigPharma #EAS2026 #ASCO2026 #EULAR2026 #Ozempic #Mounjaro #Keytruda #PharmaceuticalIndustry

In 2025, just 10 drugs generated more than 180 billion dollars in global revenue. #Keytruda (pembrolizumab) led with 31.7B, followed by #Mounjaro (tirzepatide) and #Ozempic (semaglutide) ipharmacenter.com/post/the-pharm… #news #media #pharma #ASCO2026 #EULAR2026 #healthcare

#EULAR2026 - BE BOLD is truly a bold study in the #psoriaticarthritis space. #Bimzelx achieved superior ACR50 at Week 16 vs #Skyrizi, with numerically higher MDA and PASI100, all in a single H2H trial ipharmacenter.com/post/eular-ann… #news #breakingnews #healthcare #RheumAlert #UCBPharma

#BREAKING - #China’s NMPA has approved Elunate + Tyvyt for locally advanced/metastatic #renalcellcarcinoma after VEGFR-TKI failure. FRUSICA-2 showed median PFS of 22.2 months vs 6.9 months, with ORR 60.5% vs 24.3% ipharmacenter.com/post/china-app… #RCC #KidneyCancer #Oncology #ASCO2026

#Lynozyfic (linvoseltamab) shows 100% hematologic response and rapid deep remissions in second‑line systemic #ALamyloidosis in the Phase 1/2 LINKER‑AL2 trial Full #ASCO2026 coverage @ipharmacenter ipharmacenter.com/post/american-… #Cancer #OncoAlert #innovation #oncology #news #breaking

#BREAKING | #ATS2026 #Orlando #Sanofi's efdoralprin alfa beat standard plasma-derived therapy in phase 2 ElevAATe trial: 👉3x higher fAAT levels 👉 Normal fAAT for 100% of days (vs 41%) Find details: ipharmacenter.com/post/american-… #Pharma #ATS26 #Pulmonology #news #media #BreakingNews

#Roche is set to present major #giredestrant data at #ASCO2026, spotlighting its potential to reshape treatment in ER-positive, HER2-negative #breastcancer ipharmacenter.com/post/american-… #Cancer #OncoAlert #ASCO26 #innovation #oncology #news #media #healthcare #breaking #cancerResearch

#BREAKING - In the BE BOLD head-to-head PsA trial, #Bimzelx delivered higher #ACR50 responses at Week 16 than #Skyrizi, with faster joint and skin improvements ipharmacenter.com/post/eular-ann… #news #breakingnews #healthcare #EULAR26 #EULAR2026 #RheumAlert #immunology #innovation